FP2B — Affinage

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FP2B (PF3D7_1115300) is an active papain-family cysteine protease expressed as an enzyme during the erythrocytic trophozoite stage of P. falciparum (PMID:16595182, PMID:16095562). Its refolded mature protease domain is an acidic hemoglobinase with pH optima of 5.5–7.0, a reducing-agent requirement, and hemoglobin-hydrolyzing activity biochemically similar to the closely related isozyme falcipain-2 (97.5% sequence identity), from which it is distinguished by greater substitution tolerance at position 149 (PMID:16337629, PMID:16095562). Active-site mutagenesis identified residues I85, S149, and A151 as structurally critical for catalysis, since double mutants at these positions abolished activity (PMID:16095562). Beyond hemoglobin, recombinant FP2B selectively cleaves host erythrocyte ankyrin but not protein 4.1 in an inside-out-vesicle assay, implicating it in erythrocyte cytoskeletal proteolysis relevant to parasite egress (PMID:16595182). FP2B is a component of an ~200-kDa food-vacuole complex that also contains plasmepsin II, plasmepsin IV, histo-aspartic protease, and heme detoxification protein (HDP), which together drive hemoglobin degradation and hemozoin formation; in vitro, FP2B and HDP efficiently convert hemoglobin to hemozoin (PMID:23471987). FP2B is inhibited by 1,4-benzodiazepine-based peptidomimetic aspartyl-aldehyde compounds, establishing it as a druggable cysteine protease (PMID:16722625).

Mechanistic history

Synthesis pass · year-by-year structured walk · 6 steps

2005 Medium
Establishing that the FP2B protease domain is an autonomous, active hemoglobinase answered whether this near-identical paralog of falcipain-2 retains catalytic hemoglobin-degrading function.

Evidence Recombinant mature domain expressed and refolded in E. coli, assayed against peptide substrates and hemoglobin with inhibitor profiling

PMID:16337629
Open questions at the time
- Activity shown only in vitro on isolated recombinant domain, not in the native food-vacuole context
- Contribution of FP2B versus falcipain-2 to in-cell hemoglobin turnover not resolved
2005 Medium
Active-site mutagenesis defined which residues are catalytically essential and revealed a functional divergence from the nearly identical isozyme FP2A despite 97.5% identity.

Evidence Site-directed mutagenesis (S149A/I85M and S149A/A151D double mutants) with enzymatic activity readout and sequence analysis

PMID:16095562
Open questions at the time
- Single-residue contributions not fully separated within double mutants
- No structural model to explain differential position-149 tolerance versus FP2A
2006 Medium
Orthogonal enzymatic assays confirmed the full recombinant enzyme is proteolytically active and stage-restricted, anchoring FP2B as a trophozoite-expressed cysteine protease.

Evidence Recombinant bacterial expression, fluorescent peptide cleavage, in-gel gelatin zymography, and RT-PCR staging

PMID:16595182
Open questions at the time
- No demonstration of native protein localization or endogenous activity
- Physiological substrate spectrum not defined by these assays alone
2006 Medium
A selective erythrocyte-substrate cleavage assay tested whether FP2B acts on host cytoskeletal proteins, linking it to a potential egress-related role.

Evidence Erythrocyte inside-out-vesicle assay with recombinant FP2B showing cleavage of ankyrin but not protein 4.1

PMID:16595182
Open questions at the time
- Single in vitro method without genetic confirmation of an egress role
- Cleavage of ankyrin in intact infected cells not demonstrated
2006 Low
Inhibitor profiling established that FP2B is chemically tractable, validating it as an antimalarial target.

Evidence Enzyme inhibition assays of recombinant FP2B with 1,4-benzodiazepine aspartyl-aldehyde peptidomimetics

PMID:16722625
Open questions at the time
- Mechanistic detail limited to inhibition potency, no structural basis of inhibition
- Selectivity over FP2A not resolved
- No cellular or parasite-killing correlation reported
2013 Medium
Complex characterization placed FP2B within a food-vacuole hemoglobin-degradation machine, connecting its protease activity to hemozoin biogenesis.

Evidence Co-IP/MS, gel filtration co-elution, glycerol gradient sedimentation, and in vitro Hb-to-Hz conversion of the ~200-kDa complex containing plasmepsin II/IV, HAP, and HDP

PMID:23471987
Open questions at the time
- The study uses 'falcipain 2/2'' and does not fully distinguish FP2A from FP2B within the complex
- Stoichiometry and direct FP2B contacts within the complex not defined

Open questions

Synthesis pass · forward-looking unresolved questions

The endogenous, gene-specific role of FP2B distinct from its near-identical paralog FP2A remains unresolved.
No genetic knockout/knockdown phenotype specific to FP2B in the corpus
In-cell localization and native function separated from FP2A not established
No structure of FP2B

Mechanism profile

Synthesis pass · controlled-vocabulary classification

Partners

HEME DETOXIFICATION PROTEIN (HDP) [#5]HISTO-ASPARTIC PROTEASE (HAP) [#5]PLASMEPSIN II [#5]PLASMEPSIN IV [#5]

Complex memberships

~200-kDa food-vacuole hemoglobin-degradation complex (with plasmepsin II, plasmepsin IV, histo-aspartic protease, and heme detoxification protein) [#5]

Evidence

Reading pass · 6 per-paper findings extracted from the source corpus

Year	Finding	Method	Journal	Conf	PMIDs
2006	Recombinant FP2B expressed in bacteria exhibits cysteine protease activity, demonstrated by cleavage of a fluorescent peptide substrate and in-gel gelatin zymography. FP2B is transcribed at the trophozoite stage of P. falciparum.	Recombinant protein expression in bacteria, fluorescent peptide substrate cleavage assay, in-gel gelatin zymography, RT-PCR	Blood cells, molecules & diseases	Medium	16595182
2006	Recombinant FP2B cleaves host erythrocyte ankyrin but not protein 4.1, as assessed by an erythrocyte inside-out-vesicle assay in vitro, suggesting a selective proteolytic role in parasite egress from red blood cells.	Erythrocyte inside-out-vesicle assay with recombinant FP2B	Blood cells, molecules & diseases	Medium	16595182
2005	The mature protease domain of FP2B (falcipain-2'), expressed in E. coli and refolded, is an active hemoglobinase with biochemical properties similar to falcipain-2: pH optima of 5.5–7.0, reducing agent requirement, and similar substrate preference. Both enzymes readily hydrolyze hemoglobin in vitro.	Recombinant protein expression and refolding in E. coli, enzymatic activity assays with peptide substrates and hemoglobin, inhibitor profiling	Experimental parasitology	Medium	16337629
2005	FP2B (PF11_0161) is highly expressed as an active enzyme during the erythrocytic stage. Site-directed mutagenesis of active-site-proximate residues (S149A/I85M and S149A/A151D double mutants) rendered FP2B completely inactive, identifying I85, S149, and A151 as structurally critical residues. FP2B is more tolerant to substitution at position 149 than FP2A despite 97.5% sequence identity between the two isozymes.	Active-site mutagenesis, enzymatic activity assays, bioinformatic sequence analysis	Biochemical and biophysical research communications	Medium	16095562
2006	Peptidomimetic compounds based on a 1,4-benzodiazepine scaffold with a C-terminal aspartyl aldehyde provide significant inhibitory activity against FP2B (and FP2A), confirming FP2B is a druggable cysteine protease target.	Enzyme inhibition assays with recombinant FP2B using synthetic peptidomimetic inhibitors	Journal of medicinal chemistry	Low	16722625
2013	FP2B (falcipain 2/2') is a component of an ~200-kDa protein complex in the food vacuole that also contains plasmepsin II, plasmepsin IV, histo aspartic protease, and heme detoxification protein (HDP); this complex is required for hemoglobin degradation and hemozoin formation. Co-immunoprecipitation followed by mass spectrometry, gel filtration co-elution, glycerol gradient cosedimentation, and in vitro protein interaction analyses confirmed the associations. An in vitro assay showed that falcipain 2/2' and HDP together efficiently convert hemoglobin to hemozoin.	Co-immunoprecipitation with mass spectrometry, gel filtration, glycerol gradient sedimentation, in vitro protein interaction assay, in vitro Hb-to-Hz conversion assay	Proceedings of the National Academy of Sciences of the United States of America	Medium	23471987

Source papers

Stage 0 corpus · 7 papers · ranked by NIH iCite citations

Year	Title	Journal	Citations	PMID
2004	Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum.	Proceedings of the National Academy of Sciences of the United States of America	245	15070727
2013	Protein complex directs hemoglobin-to-hemozoin formation in Plasmodium falciparum.	Proceedings of the National Academy of Sciences of the United States of America	131	23471987
2006	Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum.	Molecular and biochemical parasitology	125	16890302
2006	Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents.	Journal of medicinal chemistry	57	16722625
2005	Plasmodium falciparum: biochemical characterization of the cysteine protease falcipain-2'.	Experimental parasitology	53	16337629
2005	Characterization of amino acid variation at strategic positions in parasite and human proteases for selective inhibition of falcipains in Plasmodium falciparum.	Biochemical and biophysical research communications	10	16095562
2006	Cloning and characterization of Plasmodium falciparum cysteine protease, falcipain-2B.	Blood cells, molecules & diseases	9	16595182